射血分数保留的心力衰竭的临床表型。

Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction.

机构信息

Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

出版信息

Heart Fail Clin. 2021 Jul;17(3):483-498. doi: 10.1016/j.hfc.2021.02.009.

DOI:10.1016/j.hfc.2021.02.009

PMID:34051978

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for more than one-half of patients with heart failure. Effective treatment of HFpEF has not been established, largely because of the complexities and heterogeneity in the phenotypes of HFpEF. Categorizing patients based on clinical and pathophysiologic phenotype may provide more targeted and efficacious therapies. Despite this clinical need, there is no consensus on how to categorize patients with HFpEF into phenogroups. Possible metrics include the presence or absence of specific comorbidities that influence pathophysiology, imaging, hemodynamics, or other biomarkers. This article describes currently recognized phenotypes of HFpEF and potential treatment strategies.

摘要

射血分数保留的心力衰竭（HFpEF）占心力衰竭患者的一半以上。HFpEF 的有效治疗尚未确定，主要是因为 HFpEF 表型的复杂性和异质性。根据临床和病理生理表型对患者进行分类可能提供更有针对性和更有效的治疗方法。尽管有这种临床需求，但如何将 HFpEF 患者分类为表型群尚无共识。可能的指标包括是否存在影响病理生理学、影像学、血液动力学或其他生物标志物的特定合并症。本文描述了目前公认的 HFpEF 表型和潜在的治疗策略。